Stenting an angiographically intermediate but functionally non-significant stenosis is controversial. Nevertheless, it has been questioned if deferral of a functionally non-significant lesion on the basis of fractional flow reserve (FFR) measurement, is safe, especially on the long term. Five-year follow-up of the DEFER trial showed that outcome after deferral of percutaneous coronary intervention (PCI) of an intermediate coronary stenosis based on FFR ≥ 0.75 is excellent and was not improved by stenting. The aim of this study was to investigate the validity of this position on the very long term.
Introduction
It has been well documented that decisions with respect to revascularization of coronary stenoses should take into account not only angiographic criteria but also non-invasive or invasive evidence of reversible myocardial ischaemia. 1 -7 Stenting an angiographically significant but functionally non-significant stenosis is controversial. 8, 9 Nevertheless, it has been questioned if deferral of revascularization of a functionally non-significant lesion on the basis of fractional flow reserve (FFR) measurement is safe, especially over the long term. Concerns about future plaque rupture have played a major role in that discussion. 10 -13 The DEFER study was the first randomized controlled trial investigating the suitability of FFR to guide coronary interventions. 14 The purpose of the DEFER study was to compare deferral vs. performance of percutaneous coronary intervention (PCI) of an anatomic intermediate but functionally non-significant stenosis as indicated by FFR ≥ 0.75. The 2-and 5-year follow-up showed that, both with respect to outcome and to symptoms, deferral was at least as good as mechanical revascularization of such stenoses. Up to 5 years, there was no difference with respect to mortality, myocardial infarction (MI), or revascularization related to the deferred lesions. No differences were present either with respect to functional class or use of medication. 15 The present report extends that follow-up to 15 years with respect to the outcome parameters: mortality, MI, and revascularization.
Methods

Design and participants
The design and methods of the DEFER study have been described previously and are summarized briefly below. 14 The DEFER study was a multicenter, international, randomized controlled trial performed in 12 European and 2 Asian centres between 1997 and 1998. Patients were enrolled if they met two inclusion criteria: (i) referral for elective PCI of a single angiographically significant de novo stenosis (.50% diameter reduction by visual assessment) in a native coronary artery with a reference diameter of .2.5 mm and (ii) no conclusive evidence of reversible ischaemia as documented by non-invasive testing within the last 2 months. Main exclusion criteria were total occlusion of the target artery, MI, or unstable angina. The institutional review boards of all centres approved the study protocol. All patients provided written consent before enrolment.
Randomization
In order to prevent bias, patients were randomized before measuring FFR ( Figure 1 ). After inclusion in the study and before physiological measurement, patients were randomized to deferral or performance of PCI. Thereafter, FFR was measured. If the FFR value was ,0.75 indicating reversible ischaemia, then randomization was ignored and PCI was performed anyway because it was felt unethical at that time to leave such a stenosis unrevascularized (Reference group). In contrast, if the FFR value was ≥0.75, then the stenosis was treated according to the randomization, resulting in one group of patients with FFR ≥ 0.75 in whom PCI was performed (Perform group) and a second group of patients with FFR ≥ 0.75 in whom PCI was deferred and the further treatment was medically (Defer group). All patients received optimal medical therapy for that era.
Quantitative angiography and fractional flow reserve measurement
Angiograms were performed in at least two orthogonal projections after administration of intracoronary nitroglycerin. All angiograms were analysed using QCA-CMS system (Medis, Leiden, the Netherlands). Fractional flow reserve was measured with a coronary pressure wire (Radi Medical Systems, Uppsala, Sweden) and adenosine-based hyperaemia given intravenously (140 mg per minute per kg of body weight) or intracoronary. 16, 17 Percutaneous coronary intervention was performed according to the standards at that time, before the era of drug-eluting stents, by either bare metal stents (BMS) or balloon angioplasty.
Endpoints
The primary endpoint was freedom from major adverse cardiac events (death, MI, and repeat revascularization) after 2 years of follow-up, and 5-year follow-up was a secondary endpoint. It should be noted that the DEFER study was not powered for a 15-year follow-up and that no a priori hypothesis for such long-term follow-up was defined. The 15-year followup was added later due to the importance of understanding long-term clinical outcomes after FFR-guided revascularization. Because non-cardiac mortality will dominate cardiac mortality during such very long-term follow-up, we distinguished among cardiac, unknown, and non-cardiac mortality. Myocardial infarction was defined as a clinical episode of typical chest pain with development of new pathologic Q-waves on the electrocardiogram or an increase of serum creatinine kinase (CK) levels to more than twice the normal value, reflecting the practice pattern during the era of patient recruitment. Repeated angiography was only performed if clinically indicated or in case of an adverse event. While events were adjudicated by a clinical event committee up to 5 years, events thereafter were site determined and verified by source documentation (including related vessel, cardiac enzymes, and cause of death).
National database
In those patients for whom no complete follow-up could be acquired, applicable national databases were queried to obtain the survival status. These data were used only for comparing all-cause mortality.
Statistical analysis
All analyses used an intention-to-treat assignment. Continuous variables are expressed as mean + 1 SD and were compared using Student's t-test. Dichotomous variables are expressed as absolute numbers and percentages (%) and were compared using the x 2 test or Fisher's exact test as appropriate. Myocardial infarction rates were visualized with the use of Kaplan -Meier survival curves, using the log-rank test for the comparison between groups. A P-value of ,0.05 was considered significant, and applicable tests were always two sided. All analyses were conducted using SPSS 19.0.0.1 software (IBM Corporation, Armonk, NY, USA) or R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics and procedural results
Of 325 patients, 167 were randomly assigned to deferral and 158 to performance of PCI ( Figure 1) . Baseline characteristics of patients in both randomization arms were similar, including angiographic characteristics and FFR ( Table 1) . Fractional flow reserve was ≥0.75 in DEFER 15-year follow-up 181 patients of whom 91 belonged to the group randomized to deferral of PCI (Defer group) and 90 to the group randomized to performance of PCI (Perform group). Fractional flow reserve was ,0.75 in 144 patients. In the latter group (Reference group), randomization was ignored and PCI was performed anyway. Mean percent diameter stenosis was more severe in the Reference group (FFR , 0.75). However, overlap of data was so large that quantitative coronary angiography was absolutely not useful for predicting the true functional stenosis severity in individual patients. Fractional flow reserve was 0.86 + 0.06 in the Defer group, 0.87 + 0.07 in the Perform group, and 0.57 + 0.16 in the Reference group. In the Performance group, 41 patients (46%) were treated by BMS and 85 patients (59%) in the Reference group. Finally, all angiographic parameters after PCI were similar in the Perform and Reference groups, indicating that no difference was present in the quality of stenting between the Perform and Reference groups.
15-year follow-up
Complete follow-up was obtained in 325 patients (100%) after 12 months, in 317 patients (98%) after 24 months, in 313 patients (97%) after 5 years, and in 298 patients (92%) after 15 years. Mean follow-up of patients alive was 16.9 years (interquartile range 16.0 -17.5 years). Patients lost to follow-up were similarly distributed among Defer (10 of 91, 11%), Perform (6 of 90, 7%), and Reference (11 of 144, 8%) groups (P ¼ 0.62). Follow-up with respect to all-cause mortality after 15 years was obtained in 311 patients (96%) by checking national databases.
Clinical outcome after 15 years Mortality
Mean age of the patients at the start of the study was 61 years. Consequently, after a mean follow-up of 16.9 years, a considerable portion of patients had died from a predominance of non-cardiac causes. There was no difference in all-cause mortality after 15 years among the three groups: 33.0% in the Defer group, 31.1% in the Perform group, and 36.1% in the Reference group (Defer vs. Perform, RR 1.06, 95% CI: 0.69-1.62, P ¼ 0.79) ( Table 2) . Also cardiac death was not different between 5.5% in the Defer group, 4.4% in de Perform group, and 10.4% in the Reference group (Defer vs. Perform P ¼ 1.00).
Myocardial infarction
The rate of MI was significantly lower in the Defer group (2.2%) compared with the Perform group (10.0%), RR 0.22, 95% CI: 0.05 -0.99, P ¼ 0.03. This was almost exclusively due to less target vessel-related infarctions (Figure 2 ). Patients with a baseline FFR ≥ 0.75 had a significantly lower rate of MI compared with patients with an FFR , 0.75 (6.1 vs. 12.5%, RR 0.49, 95% CI: 0.24-1.00, P ¼ 0.044).
Repeat revascularization
Revascularization occurred in 42.9% of the Defer group, 34.4% of the Perform group, and 44.4% of the Reference group, thereby showing a trend towards higher revascularization rate in the Defer group (Defer vs. Perform P ¼ 0.245). However, when looking at total cumulative events, no difference was observed (47 vs. 49 events) regarding PCI, as shown in Table 3 . In other words, the mean number of percutaneous coronary interventions per patient was not statistically different in both groups.
Discussion
The DEFER randomized controlled trial investigated the safety of deferring PCI for an angiographically significant but functionally nonsignificant coronary stenosis as indicated by an FFR ≥ 0.75. Our results show that even after 15 years of follow-up, the prognosis of functionally non-significant deferred lesions is excellent, that PCI of such stenoses has no advantage and even results in more MIs when compared with medical therapy. Our novel results extend earlier findings from the DEFER study at 2-and 5-year followup. 14, 15 This is the longest follow-up of a randomized trial using fractional flow reserve for decision making and calls for a number of discussion points. First, our results show a significant increase in rates of MI if a functionally non-significant stenosis is treated by PCI compared with medical therapy alone. These MIs not only were peri-procedural but also occurred throughout the complete follow-up, with the majority arising later than 5 years after the index procedure ( Figure 2) . Interestingly, in the Defer group only one MI was possibly related to the study vessel, thereby confirming the excellent natural history of a functionally non-significant stenosis with optimal medical treatment. In contrast, in the Perform group, the majority of MIs occurred in the stented artery, suggesting a possible role of neo-atherosclerosis as underlying cause.
Second, despite the increased rate of MI in the Perform group, there was no increased mortality compared with the Defer group. In this respect, it should be noted that after a very long-term followup mortality is more related to advanced age (average age of 78.0 years at mean follow-up) and non-cardiac causes than to cardiac death. Therefore, the potential effects of deferral vs. performance of PCI on mortality dilute over time. However, the present data show that concerns about increased mortality after deferral of angiographically significant but functionally non-significant coronary lesions are not justified. 10, 12, 13 Third, deferring PCI of functionally non-significant stenoses does not result in a significant increase or 'catch-up' of revascularization compared with PCI on the long term. There was a trend towards revascularization occurring in more patients in the Defer group compared with the Perform group, but when looking at total cumulative events no difference was observed (Table 3) .
Fourth, the current study provides unique insights into the natural course of coronary artery disease over the very long term when treated medically according to FFR guidance. Several studies have described the follow-up of medically treated coronary stenoses in stable angina, but none of them exceeded 10 years. 18 -20 Direct comparison of our results with other studies should be done with caution due to differences in baseline characteristics. Deferral of PCI in angiographically significant but functionally non-significant lesions is safe during the very long term. The current study presents rates of MI in the Defer group of 2.2% after 15 years, compared with MI rates of 11.2% after 5 years in COURAGE, and 4.5% after 7 years in RITA-2, when FFR was not used in comparable patients. 18, 21 In the FAME study, of 513 deferred lesions based on an FFR . 0.80, only one infarction related to a deferred lesion occurred after 2 years, in line with our extended DEFER results.
Limitations
The present study also has several limitations. First, the study was not designed for a follow-up of 15 years and was therefore not explicitly powered for the reported endpoints. Second, PCI was performed in an era when drug-eluting stents were not yet available. With contemporary second-generation stents the rate of MI might have been lower in the Perform group. 22 Yet, the excellent outcome in the Defer group, with only two MIs, is hard to surpass (Figure 2) .
Third, although treatment was randomized, neither the patients nor the physician was blinded. This might have created a bias towards more revascularization in the Defer group at follow-up.
Fourth, in contrast to contemporary patients, the majority of patients in the DEFER study had single vessel disease. Extrapolating our long-term data to patients with multivessel disease should be done with caution. Nevertheless, comparable results with respect to deferral of functionally non-significant lesions up to 5 years have been described in patients with multivessel disease in the FAME and FAME 2 studies. 5, 7 Therefore, even in multivessel disease it might be expected that PCI can be safely deferred in functionally nonsignificant lesions. Finally, when using FFR to identify ischaemic stenoses, a grey zone exists between 0.75 and 0.80. In the DEFER study, the lower limit of that grey zone was used, whereas presently the upper limit of the grey zone is used (0.80) to make decisions, thereby increasing sensitivity to almost 100% at the cost of a decreased specificity. We do not believe this choice fundamentally influenced the outcome of the DEFER study because of a continuous relationship between the FFR value and clinical outcomes for both deferral and performance of PCI, as documented recently in a large meta-analysis. 3 
Conclusion
In conclusion, among patients with stable chest pain, coronary stenoses that are not responsible for inducible ischaemia as indicated by FFR ≥ 0.75 have an excellent outcome when treated medically, even after 15 years of follow-up. Performing PCI of such functionally non-significant stenosis has no benefit compared with medical treatment.
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